Abstract 4778
Background
Gastric cancer is one of the most common fatal disease worldwide, but its mechanism and therapeutic targets are still unclear. In this study, we have analyzed the differences in gene modules and key pathways in gastric cancer patients, and elaborated the mechanism and effective treatment of gastric cancer with microarray data from the gene expression omnibus (GEO) database.
Methods
GEO2R tools was used to identify differential expression genes (DEGs) and String database was employed to construct protein-protein interaction (PPI) network. We firstly imported the PPI network into the Cytoscape software to find key nodes, and then employed the DAVID database to enrich and annotate the pathways and key modules.
Results
63 characteristic genes of gastric cancer are involved in regulation of ECM-receptor interaction, focal adhesion and Protein digestion and absorption. SPARC, FN1, BGN and COL1A2 are four key nodes relating to tumour proliferation and metastasis, and their expression were strongly associated with poor survival (p < 0.05). 13 transcription factors including PRRX1 have remarkable changes in gastric cancer.
Conclusions
The crucial genes and pathways of gastric cancer were explored through different perspectives via multiple bioinformatics methods. Our study will not only contribute to elucidating the pathogenesis of gastric cancer, but also provide prognostic markers and potential therapeutic targets for gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (No. 81503165), Natural Science Foundation of Zhejiang Province (No. Q17H310010).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3240 - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study
Presenter: Maria Alsina
Session: Poster Display session 2
Resources:
Abstract
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract